ElectraDx has developed the first lab-accurate, ultra-low-cost community ad home based diagnostic platform using proprietary intelligent electronic strip technology. Our device delivers results from a simple fingerstick in under10 minutes, connects securely to healthcare systems, and supports a broad test menu covering over 70% of common lab tests. With an initial focus on cardiac markers, we are shifting diagnostics from hospitals into every home to enable earlier intervention and better health outcomes.

Visit our website to learn more.

Amplifi Vascular is developing the Amplifi™ Vein Dilation System, a proprietary blood pump technology designed to enlarge veins and improve outcomes for patients requiring arteriovenous fistula (AVF) surgery. The system is intended to increase AVF eligibility, accelerate maturation, reduce failure rates, and extend primary patency. By addressing key challenges in dialysis access, Amplifi aims to improve treatment outcomes for patients with end-stage renal disease.

HapticHeart Solutions is advancing a wearable haptic feedback platform—featuring a glove and armband—that restores tactile sensation in catheter-based, minimally invasive, and robotic procedures. By converting physical and physiological signals into real-time touch and force feedback, the system aims to enhance surgical precision, shorten learning curves, and improve patient outcomes. Currently at Technology Readiness Level 6, the prototype has demonstrated clinical utility in electrophysiology and is being expanded for use in robotic surgery.

Nitinotes Ltd. is an early commercial-stage medical device company advancing endoluminal innovation for obesity care. Its flagship platform, EndoZip™, is the first fully automated, single-operator suturing system designed specifically for endoscopic sleeve gastroplasty (ESG). EndoZip™ is engineered to improve procedural workflow, support consistency, and enhance scalability of ESG while keeping physicians in control of technique and outcomes. The company received CE Mark approval in November 2025 and has initiated focused European commercialization, including its first commercial case in Italy. In the United States, EndoZip™ is an investigational device, currently being evaluated in the pivotal EASE clinical trial. Nitinotes is positioned at the intersection of metabolic intervention, procedural innovation, and growing global demand for minimally invasive obesity solutions.

RIVANNA® is a medical technology company developing clinical decision-support solutions powered by proprietary clinical datasets, AI models, and purpose-built imaging hardware. The company's platform automates complex anatomical analysis at the point of care, enabling faster, more confident clinical decisions while reducing variability and expanding access to advanced capabilities. The first applications target significant market opportunities in regional anesthesia and fracture care.

HeartFocus is an FDA-cleared, AI-powered cardiac ultrasound platform designed to radically expand access to echocardiography. The software provides real-time acquisition guidance and automatic quality validation, enabling clinicians with minimal ultrasound training to consistently capture diagnostic-quality transthoracic echocardiographic views. By shifting image acquisition from scarce specialists to a broader clinical workforce — including nurses, PAs, and frontline providers - HeartFocus addresses a critical bottleneck in cardiac care across emergency medicine, primary care, and resource-limited environments.HeartFocus is FDA cleared and commercially available in the United States, with early customers live and active across multiple care settings - positioning the platform for rapid scale in preventive, acute, cardiac care, and educational institutions.

The Yacoub Heart Valve: A unique, tissue-engineered valve that promises to revolutionise heart valve replacement with no compromises. Using intricate scaffold technology that transforms in-situ into a living heart valve, using the body's own healing processes to regenerate as nature intended. Restoring full life expectancy and in kids, adapting and growing.

Inossia is developing a platform technology focused on reducing repeat fractures in patients receiving bone cement for fracture repair. The company's lead product, V-Flex, is a bone cement for vertebral augmentation that hardens at a significantly lower temperature compared to competing bone cements. The soft cement is ideal for osteoporotic bones to adjacent fracture risk without compromising on mechanical support.

Paradromics is building the world's most capable and clinically viable brain-computer interface (BCI) platform. Its advanced neurotechnology captures brain activity at the highest resolution, individual neurons, enabling AI-powered treatments for motor impairment, chronic pain, addiction, depression, and other neurological conditions. The company's first clinical product, Connexus® BCI, is designed to restore speech and communication for people who are unable to speak due to debilitating motor conditions.

OLI is a medical device company developing a platform for accessible, affordable kidney care. The company is building compact, low-cost systems to unlock clinical-quality hemodialysis and hemodiafiltration therapies for kidney failure patients from virtually anywhere.

Berlin Heals is developing the C-MIC system, an implantable electroceutical device that delivers a constant, but minimal, electrical direct current that mimics the physiological electrical currents produced by the heart. The device is a near-curative treatment for patients with heart failure that propagates the reverse remodeling of cardiac muscle tissue to restore heart function and size, thereby reducing the symptoms of heart failure and improving quality of life.

Accure Medical is revolutionizing dermatology with the Accure Laser System, the first 1726nm platform to achieve both CE Mark certification and FDA clearance for the long-term treatment of mild to severe inflammatory acne vulgaris. Leveraging its patented treat-to-temperature technology, the system ensures consistent, safe, and effective results for all skin types. With rapid adoption across the US, Europe, Asia, and the Middle East, Accure is addressing a significant global need with its groundbreaking solution for acne treatment.

cMAP® is an AI-enabled PAP platform algorithm that predicts and prevents respiratory episodes before they occur. Its personalized approach delivers therapy at lower, more comfortable pressures — driving significantly better patient adherence.

Panda Surgical, a University College London spinout, is introducing the world's first robotics and AI platform for minimally invasive neurosurgery, offering surgeons enhanced dexterity and decision-support to make these operations safer, more effective, and more widely adopted.

MDA is building a best-in-class surgical reference database and translating the expertise of leading surgeons into advanced, AI-powered intra-operative decision-support solutions. Backed by €4 million in seed capital, MDA has successfully validated its business model over the past 24 months. To unlock the full potential of its approach and secure long-term market leadership, MDA is now seeking further growth capital. The company logo and the presenter's photo are attached to this mail

Retia develops healthtech AI algorithms for helping guide management of surgical and critically ill patients to improve outcomes. This is a $4 billion market. The company's technology has been clinically validated and is used in 65 hospitals.

Moximed is a commercial-stage medical device company offering the MISHA Knee System, an FDA-authorized Implantable Shock Absorber designed to treat medial knee osteoarthritis. The device is placed on the inner side of the knee during an outpatient procedure to absorb the impact of walking, reducing joint force by 30%. Differentiated by its joint-preserving design that does not require cutting bone, Moximed bridges the gap between conservative therapies and total knee replacement, offering active patients superior pain relief and mobility.

FORESEE MedTech is a deep-tech spin-off awardee of the European Innovation Council (EIC) Transition grant (2.5 M€), that is developing an intravascular multiparametric sensing platform for remote monitoring of chronic conditions, starting with heart failure. FORESEE’s solution aims to support earlier interventions, reduce hospitalizations, empower patients and improve long-term outcomes in this cardiovascular condition. Thanks to the ability to measure multiple parameters from a single intravascular device, FORESEE will improve patient management by addressing the fact that in heart failure "one size does not fit all  

Vivifi Medical is pioneering the first non-surgical, non-urethral device for treating BPH that targets the hormonal root cause rather than simply managing symptoms. By redirecting testosterone-rich blood away from the prostate, our approach results in true regression without implants, urethral instrumentation, or compromise to sexual function.

LuSeed's DOME is a minimally invasive device for treating bifurcation and sidewall brain aneurysms simply and effectively. The device utilizes a braided mesh design that makes it position-agnostic within the aneurysm. Another benefit of the DOME device is its design, which minimizes protrusion to the parent artery, thereby mitigating the need for dual anticoagulation therapy.

Arctx Medical, a clinical-stage medical technology company, is developing the world's first targeted treatment for Acute Pancreatitis (AP), and is introducing a superior new approach for patient temperature management. Targeted cooling is a well-established therapy for treating acute inflammatory conditions within the body. The Arctx Cool Catheter™ (ACC) Set delivers minimally invasive, selective, and potent cooling therapy to the pancreas, intended to reduce inflammation, accelerate patient recovery, and prevent more serious complications including organ failure and death. Arctx is embarking on an IDE-approved US pivotal clinical trial for this first-ever dedicated treatment for AP. In addition, Arctx now has FDA clearance for the ACC for patient temperature management, a second and mature market for its technology in which it is beginning to commercialize.

CleanMargin is a clinical-stage company developing the proprietary fluorescent surgical imaging agent, MarginVue, that enables surgeons to precisely visualize and remove all cancer lesions during breast-conserving cancer surgeries to achieve clean (cancer-free) surgical margins, addressing a large unmet medical need in breast cancer and many other cancer surgeries. Our ongoing Phase II clinical trials conducted at Memorial Sloan Kettering Cancer Center together with our device partner, Stryker Corp., demonstrate that MarginVue is safe and detects all sub-types of breast cancer with 100% sensitivity

YOPI has developed a proprietary wearable device, worn on the upper arm, that continuously analyzes sweat to monitor key physiological electrolytes and metabolic markers in real time. The technology enables early identification of cardiovascular risk indicators—well before clinical symptoms appear, while delivering advanced performance insights, including real-time oxygen consumption (VO₂), accurate calorie expenditure, and substrate utilization (fat, carbohydrates, and proteins), along with additional critical physiological metrics. This non-invasive platform replaces traditional offline VO₂ testing and intermittent blood-based diagnostics with continuous, real-time, and clinically relevant health monitoring—effectively bringing the metabolic lab into everyday life.